Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$1.57 AUD
Change Today +0.025 / 1.62%
Volume 477.6K
As of 12:57 AM 10/7/15 All times are local (Market data is delayed by at least 15 minutes).

australian pharma indus ltd (API) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/27/15 - A$1.91
52 Week Low
10/14/14 - A$0.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

australian pharma indus ltd (API) Related Businessweek News

No Related Businessweek News Found

australian pharma indus ltd (API) Details

Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical and associated products to pharmacies in Australia. The company operates in three segments: Pharmacy Distribution, Retailing, and Manufacturing. It also provides finance origination and retail services to pharmacists under the Soul Pattinson and Pharmacist Advice banners, as well as offers product delivery, marketing programs, and business advisory services. In addition, the company purchases and sells health, beauty, and lifestyle products in the retail industry under the Priceline brand, as well as operates as a franchisor with approximately 150 Priceline Pharmacy stores. Further, it manufactures and owns rights of pharmaceutical medicines and consumer toiletries in New Zealand. The company was founded in 1910 and is based in Camellia, Australia.

Founded in 1910

australian pharma indus ltd (API) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$910.7K
Group General Manager of Business Development...
Total Annual Compensation: A$604.7K
Chief Legal Counsel and Company Secretary
Total Annual Compensation: A$397.8K
Group General Manager of People
Total Annual Compensation: A$371.6K
Compensation as of Fiscal Year 2014.

australian pharma indus ltd (API) Key Developments

Australian Pharmaceutical Industries Limited Announces the Appointment of Kenneth W Gunderson-Briggs as Senior Independent Director

The Board of Australian Pharmaceutical Industries Limited announced the appointment of Mr. Kenneth W Gunderson-Briggs as Senior Independent Director. Ken Gunderson-Briggs was first appointed to the API Board in May 2014.

Solomon Lew Reportedly Mulls Sale Of Stakes In Australian Pharmaceutical Industries

Solomon Lew reportedly is seeking sale of stakes in Australian Pharmaceutical Industries Limited (ASX:API). Stockbrokers are seeking to offload Solomon Lew’s 12% in Australian Pharmaceutical Industries. Solomon Lew privately owned SL Nominees has more than 58.1 million shares in Australian Pharmaceutical Industries.

Australian Pharmaceutical Industries Limited Declares Fully Franked Interim Dividend, Payable on 5 June 2015; Reports Unaudited Consolidated Earnings Results for the Six Months Ended February 28, 2015

Australian Pharmaceutical Industries Limited reported unaudited consolidated earnings results for the six months ended February 28, 2015. For the period, the company reported revenue of AUD 1,712,369,000 against AUD 1,658,749,000 a year ago. Results from operating activities were AUD 38,582,000 against results from operating activities negative of AUD 78,015,000 a year ago. Loss before tax was AUD 31,411,000 against profit before tax of AUD 107,739,000 a year ago. Profit for the period was AUD 21,269,000 against loss for the period of AUD 114.937.000 a year ago. Basic and diluted profit per share was 4.4 cents against loss per share of 23.5 cents a year ago. Net cash from operating activities was AUD 51,128,000 against AUD 29,128,000 a year ago. Acquisition of property, plant and equipment was AUD 3,929,000 against AUD 4,157,000 a year ago. Underlying net profit after tax was AUD 21,444,000 against AUD 16,237,000 a year ago. The company announced that the board has declared a fully franked interim dividend of 2.00 cents per share. The record date for determining entitlements to the interim dividends is 8 May 2015. The dividend will be paid on 5 June 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
API:AU A$1.57 AUD +0.025

API Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for API.
View Industry Companies

Industry Analysis


Industry Average

Valuation API Industry Range
Price/Earnings 15.1x
Price/Sales 0.2x
Price/Book 1.4x
Price/Cash Flow 15.1x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUSTRALIAN PHARMA INDUS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at